諾誠健華-B(09969.HK)曾挫30%創四個月低 獲渤健(BIIB.US)通知終止合作和許可協議
諾誠健華-B(09969.HK)今早(16日)低開14.9%,報10.36元,初段跌幅急擴,曾跌30.1%,低見8.51元,創去年10月中旬以來約四個月低。現報8.93元,跌26.68%,成交激增至1,908.3萬股,涉資1.72億元。
諾誠健華公布,獲合作夥伴渤健(BIIB.US)通知,將為便利而終止(to terminate for convenience)雙方就抑制劑產品「奧布替尼」的全球開發和商業化達成的合作和許可協議,公司將重新獲得該產品所有全球權利。
雙方於2021年7月初就奧布替尼達成許可及合作協定,根據協定條款,諾誠健華將獲得 1.25億美元首付款,以及在達到合作約定的開發里程碑、商業里程碑以及銷售里程碑時,有資格獲得至多8.125億美元的潛在臨床開發里程碑和商業里程碑付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.